

REMARKS

Reconsideration of the application is respectfully request in view of the foregoing amendment and the following remarks.

Claims 1-5, 9-11 and 14-16 are pending in the application. Claims 1-5, 9-11 and 14-16 have been rejected. Claim 14 has been amended. No new matter has been added.

Claims 3, 9 and 14 have been provisionally rejected on the ground of statutory double patenting under 35 U.S.C. §101 as claiming the same invention as that of claims 2, 19 and 30 of copending application no. 10/517,362.

In response to this rejection, an amendment (a copy of which is attached) has been submitted in copending application no. 10/517,362, wherein claims 2, 19 and 30 have been cancelled without prejudice. In view of the above, withdrawal of the rejection of claims 3, 9 and 14 under 35 U.S.C. §101 is respectfully requested.

Claims 1-5, 9-11 and 14-16 have been rejected on the ground of nonstatutory obviousness-type double patenting as being unpatentable over claims 1, 3, 18, 20-29 and 31 of copending application no. 10/517,362.

In response to this rejection, a terminal disclaimer is submitted herewith, disclaiming the term of any patent issuing on the present application, application no. 10/516,402, that would extend beyond the expiry of any patent issuing on application no. 10/517,362.

In view of the above, withdrawal of the rejection of claims 1-5, 9-11 and 14-16 under the ground of nonstatutory obviousness-type double patenting is respectfully requested.

Claims 1-5, 9-11 and 14-16 have been rejected on the ground of nonstatutory obviousness-type double patenting as being unpatentable over claims 73-81 of copending application no. 10/515,714.

In response to this rejection, a terminal disclaimer is submitted herewith, disclaiming the term of any patent issuing on the present application, application no. 10/516,402, that would extend beyond the expiry of any patent issuing on application no. 10/515,714.

In view of the above, withdrawal of the rejection of claims 1-5, 9-11 and 14-16 under the ground of nonstatutory obviousness-type double patenting is respectfully requested.


Claims 14 and 15 have been rejected under 35 U.S.C. §112, first paragraph. The Examiner contends that the specification, while being enabling for treating female gynecological disorder, does not reasonably provide enablement for preventing female gynecological disorder.

In response, to facilitate prosecution claim 14 have been amended to delete recitation of the phrase "and/or preventing".

In view of the above, withdrawal of the rejection of claims 14 and 15 under 35 U.S.C. §112, first paragraph, is respectfully requested.

A good faith effort has been made to place the present application in condition for allowance. If the Examiner believes a telephone conference would be of value, she is requested to call the undersigned at the number listed below.

Respectfully submitted,



Akzo Nobel Inc.
120 White Plains Road
Suite 300
Tarrytown, New York 10591-5522

Susan Hess.
Attorney for Applicants
Reg. No. 37,350
(973) 422-7474

Date: March 30, 2007